05274nam 2200637Ia 450 991083028280332120230725041830.01-282-55040-397866125504093-527-62948-33-527-62949-1(CKB)2520000000009703(EBL)487749(OCoLC)609856719(SSID)ssj0000364143(PQKBManifestationID)11263699(PQKBTitleCode)TC0000364143(PQKBWorkID)10393812(PQKB)11763427(MiAaPQ)EBC487749(EXLCZ)99252000000000970320071130d2010 uy 0engur|n|---|||||txtccrParkinson disease[electronic resource] a health policy perspective /edited by Wayne Martin [et al.]Weinheim Wiley-VCH Verlag GmbH & Co.c20101 online resource (362 p.)Health Care and Disease ManagementDescription based upon print version of record.3-527-32779-7 Includes bibliographical references and index.Parkinson Disease: A Health Policy Perspective; Contents; Preface; Summary and Policy Considerations; List of Contributors; Part I: Parkinson Disease - Diagnosis and Treatment; 1: Parkinson Disease; 1.1: Patient Burden; 1.2: Characteristics of Parkinson Disease; 1.3: Diagnosis of Parkinson Disease; 1.4: Treatment for Parkinson Disease; References; 2: Clinical Features of Parkinson Disease; 2.1: Introduction; 2.2: Cardinal Features; 2.3: Differential Diagnosis; 2.3.1: Essential Tremor; 2.3.2: Progressive Supranuclear Palsy; 2.3.3: Multiple System Atrophy2.3.4: Cortico-Basal Ganglionic Degeneration2.3.5: Dementia with Lewy Bodies; 2.3.6: Vascular Parkinsonism; 2.4: Non-Dopaminergic Features of PD; 2.4.1: Sleep Disturbances; 2.4.2: Olfaction; 2.4.3: Dysautonomia; 2.4.4: Neuropsychiatric Features; 2.4.4.1: Dementia; 2.4.4.2: Depression; 2.5: Natural History; 2.6: Conclusions; References; 3: Current Approaches to the Management of Parkinson Disease; 3.1: Introduction; 3.2: Pharmacologic Treatment; 3.2.1: Symptomatic Therapy; 3.2.1.1: Levodopa; 3.2.1.2: Levodopa-Induced Motor Complications; 3.2.1.3: Catechol-O-Methyl Transferase (COMT) Inhibitors3.2.1.4: Monoamine Oxidase B (MAO-B) Inhibitors3.2.1.5: Dopamine Agonists; 3.2.1.6: Managing Drug-Induced Adverse Events; 3.2.2: Neuroprotective Therapy; 3.2.3: Surgical Treatment; 3.2.4: Non-Pharmacologic Treatment; 3.3: Nursing; 3.4: Rehabilitation; 3.4.1: Physical Therapy; 3.4.2: Occupational Therapy; 3.4.3: Speech Therapy; 3.5: Nutrition; 3.6: Psychosocial Issues; 3.7: Conclusions; References; 4: Treatment of Non-Motor Symptoms of Parkinson Disease; 4.1: Sleep Disturbances; 4.2: Autonomic Dysfunction; 4.2.1: Orthostatic (Postural) Hypotension; 4.2.2: Urinary Dysfunction4.2.3: Gastrointestinal Dysfunction4.2.3.1: Dysphagia; 4.2.3.2: Gastroparesis; 4.2.3.3: Constipation; 4.2.3.4: Anorectal Dysfunction; 4.2.4: Weight Loss; 4.2.5: Sweating Disturbances; 4.2.6: Sexual Dysfunction; 4.2.7: Sialorrhea; 4.2.8: Dyspnea; 4.3: Neuropsychiatric Problems; 4.3.1: Depression; 4.3.2: Anxiety; 4.3.3: Apathy; 4.3.4: Medication-Related Psychiatric Problems; 4.3.5: Impulse Control Disorders; 4.3.6: Dopamine Dysregulation Syndrome; 4.3.7: Punding Behavior; 4.3.8: Hypersexuality; 4.3.9: Dementia; 4.3.10: Psychosis; 4.4: Sensory Symptoms and Pain; 4.4.1: Pain4.4.2: Olfactory Dysfunction4.5: Other Problems; 4.5.1: Eye Movement Abnormalities; 4.5.2: Fatigue; 4.6: Non-Motor Fluctuations; 4.7: Conclusions; References; 5: Palliative Care and End-of-Life Issues with Parkinson Disease; 5.1: Challenges in Advanced-Stage PD; 5.2: The Most Common Causes of Death in PD; 5.3: Specific Problems in the Advanced-PD Patient; 5.3.1: Pain; 5.3.2: Cognitive Decline; 5.3.3: Other Psychiatric Complications; 5.3.4: Speech and Swallowing Difficulties; 5.3.5: Bowel and Bladder Dysfunction; 5.3.6: Sleep Disturbances; 5.4: Caregiver Burden5.4.1: Placement in Long-Term Care FacilitiesPart of the successful Institute of Health Economics (IHE) book series, this handbook and ready reference adopts a unique approach in combining policy recommendations with specific treatment options for Parkinson patients.The first part of the book deals with the clinical medical, social and economical aspects of Parkinson Disease. These ten chapters include the latest diagnosis and treatment options for patients, the economical consequences, social and ethical implications and end-of life issues. The second part of the book essentially covers a large-scale case study on Parkinson in AlberHealth Care and Disease ManagementParkinson's diseaseMedical policyParkinson's disease.Medical policy.616.833616.83306Martin Wayne1715382MiAaPQMiAaPQMiAaPQBOOK9910830282803321Parkinson disease4109967UNINA